查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1492530

Devic 症候群治疗市场：按治疗方法、分销管道和最终用户划分 - 全球预测 2024-2030

Devic's Syndrome Treatment Market by Treatment (Corticosteroids, Immunosuppressants, Plasma Exchange (Plasmapheresis)), Distribution Channel (Clinics, Hospitals, Online Pharmacies), End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

Devic症候群治疗市场规模预估2023年为2,1053万美元，预估2024年达到2,2027万美元，2030年将达2,9003万美元，复合年增长率为4.68%。

Devik 综合征，也称为视神经脊髓炎 (NMO)，是一种中枢神经系统 (CNS) 慢性疾病，主要影响患者的视神经和脊髓。当免疫系统攻击健康细胞时，就会发生这种疾病，并可能导致不同程度的失明和瘫痪。治疗策略通常旨在控制症状和预防復发。透过教育和宣传宣传活动提高全世界对戴维克综合征的认识有助于促进早期诊断和早期治疗。医疗保健基础设施和可近性的改善正在增加德维奇症候群治疗方法的普及，使更多患者能够得到及时、适当的治疗。然而，潜在的副作用以及现有治疗方法无法有效治疗和管理德维奇症候群可能会降低患者对医疗保健解决方案的信任。此外，德维奇症候群的罕见性使研究经费和药物开发变得复杂，与更常见的疾病相比，这一领域的研究往往较少。探索基因疗法可能为未来提供治疗甚至治癒德维奇症候群的新方法。根据基因图谱制定个人化治疗计画有可能改善治疗结果。

主要市场统计
基准年[2023] 21053万美元
预测年份 [2024] 22027万美元
预测年份 [2030] 29003万美元
复合年增长率（%） 4.68%

区域洞察

在美洲，特别是在美国和加拿大，随着最近的标靶治疗核准，德维奇症候群的治疗选择已经大大进步。此外，强大的医疗基础设施和针对多种疾病的保险范围使患者更容易获得德维奇综合症的治疗。患者权益团体在游说保险范围和为新治疗方法研究获取资金方面发挥着重要作用。研究投资强劲，并获得美国国立卫生研究院等政府机构和私人企业的支持。欧盟 (EU) 国家在欧盟监管下共用承诺支持包括德比克氏症在内的罕见疾病领域的研究和发展。欧洲药品管理局 (EMA) 对新治疗方法的核准对于确定整个欧洲消费者的使用至关重要。病患就诊系统和政府资助对倾向于支付高额治疗费用的消费者的购买行为有重大影响。亚太地区的医疗保健系统正在迅速扩张，政府和私营部门对医疗保健的投资不断增加，包括对罕见疾病的关注。亚太地区最近的专利趋势表明，人们对开发针对德维克综合症等疾病的新治疗方法的兴趣日益浓厚，旨在促进生物技术创新的国家资助计划和倡议正在支持这一点。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在 Devic 症候群治疗市场的定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对 Devic 症候群治疗市场中供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该领域竞争性质的宝贵见解，包括累积研究期、片段化优势和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对他们目前在 Devic 综合症治疗市场中的地位进行全面评估，使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 德维克症候群的发生率在世界各地不断增加
      • 提高对神经系统疾病认识的努力和支持团体的出现
      • 有利的监管核准和政府倡议，确保获得 Devic 综合征的治疗
    • 抑制因素
      • 该疾病的复杂性和治疗方法无法解决德维奇综合征
    • 机会
      • 持续努力提高Devic症候群治疗方案的有效性和安全性
      • 患者更喜欢个人化、针对性的治疗策略
    • 任务
      • 用于治疗德维奇症候群的药物可能产生的副作用
  • 市场区隔分析
    • 治疗： 皮质类固醇用于治疗 Devic 综合征，因为它们可以有效快速抑制发炎。
    • 最终使用者：为成年患者制定全面的 Devic 症候群治疗计划
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 Devik 症候群治疗市场：依治疗分类

  • 皮质类固醇
  • 免疫抑制剂
  • 血浆置换（血浆交换）

第七章 Devik 症候群治疗市场：按分销管道

  • 诊所
  • 医院
  • 网路药房

第 8 章 Devik 症候群治疗市场：按最终用户分类

  • 成年患者
  • 儿科患者

第九章 北美和南美Devik症候群治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太德维克症候群治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章 欧洲、中东和非洲Devik症候群治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • FDA核准Ultomiris 用于治疗视神经脊髓频谱障碍，扩大了治疗范围
    • 加拿大卫生署核准UPLIZNA 用于治疗成年 NMOSD 患者
    • 中外製药针对 NMOSD 患者的 Enspring 在台湾上市
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-CB04E05660A7

[191 Pages Report] The Devic's Syndrome Treatment Market size was estimated at USD 210.53 million in 2023 and expected to reach USD 220.27 million in 2024, at a CAGR 4.68% to reach USD 290.03 million by 2030.

Devic's Syndrome, also known as neuromyelitis optica (NMO), is a chronic disorder of the central nervous system(CNS) that primarily affects the patient's optic nerves and spinal cord. The condition involves the immune system attacking healthy cells and can result in varying degrees of blindness and paralysis. Treatment strategies typically aim to manage symptoms and prevent relapses. Rising awareness of Devic's Syndrome globally through education and advocacy campaigns helps in early diagnosis and treatment. Improvements in healthcare infrastructure and accessibility allow more patients to receive timely and appropriate treatment, thereby increasing the adoption of treatments for Devic's Syndrome. However, the possibility of side effects and the inability of existing treatments to effectively target and manage Devic's Syndrome can reduce patient trust in the healthcare solution. Moreover, the rarity of Devic's Syndrome complicates research funding and drug development, often leaving this area less explored than more prevalent diseases. Exploring gene therapy could offer new ways to treat or possibly cure Devic's Syndrome in the future. Creating personalized treatment plans based on genetic profiles could improve treatment outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 210.53 million
Estimated Year [2024] USD 220.27 million
Forecast Year [2030] USD 290.03 million
CAGR (%) 4.68%

Regional Insights

In the Americas region, particularly in the United States and Canada, treatment options for Devic's Syndrome have evolved significantly with recent approvals of targeted therapies. A robust healthcare infrastructure and significant insurance coverage of several diseases have also created a favorable landscape for patients to access treatment for Devic's Syndrome. Patient advocacy groups play a crucial role in lobbying for insurance coverage and funding for research into new treatments. Investment in research is robust and supported by government bodies such as the National Institutes of Health and private enterprises. European Union countries share a commitment under EU regulations to support research and development in the field of rare diseases, including Devic's Syndrome. European Medicines Agency(EMA) approvals for new treatments are critical in defining consumer access across Europe. Patient access schemes and governmental funding significantly impact consumer purchasing behaviors, as treatments can be expensive. APAC's rapidly expanding healthcare system and increased investment in healthcare from both government and private sectors include a focus on rare diseases. Recent patents in APAC suggest a growing interest in developing novel treatments for conditions such as Devic's Syndrome, supported by state-funded programs and initiatives aimed at boosting biotechnology innovations.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Devic's Syndrome Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Growing incidences of Devic's Syndrome across the world
      • Efforts to raise awareness for neurological conditions and the emergence of advocacy groups
      • Favorable regulatory approvals and government initiatives to ensure access to Devic's syndrome treatments
    • Market Restraints
      • Complexity of the disease and the inability of treatments to tackle Devic's Syndrome
    • Market Opportunities
      • Ongoing initiatives to improve the efficacy and safety of Devic's Syndrome treatment solutions
      • Patient preference for personalized and specific treatment strategies
    • Market Challenges
      • Possibility of side effects of the treatment solutions for Devic's Syndrome
  • Market Segmentation Analysis
    • Treatment: Utilization of corticosteroids for Devic's Syndrome due to their effectiveness in rapidly controlling inflammation
    • End User: Development of a comprehensive Devic's Syndrome treatment plans for adult patients
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Devic's Syndrome Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Devic's Syndrome Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves Ultomiris for Neuromyelitis Optica Spectrum Disorder, Expanding Its Therapeutic Scope

The FDA has approved Ultomiris (ravulizumab-cwvz) for treating adult patients with neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-aquaporin-4 (AQP4) antibodies. This decision was supported by data from the phase 3 CHAMPION-NMOSD trial. Ultomiris, a long-acting C5 complement inhibitor, is also used to treat other serious conditions such as generalized myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome, highlighting its versatility in managing autoimmune and hematologic disorders. [Published On: 2024-03-25]

Health Canada Approves UPLIZNA for Adults with NMOSD

Horizon Therapeutics, a subsidiary of Amgen, announced that UPLIZNA (inebilizumab for injection) received approval from Health Canada. This approval allows it to be used as a single-agent treatment for adult patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD) who test positive for AQP4-IgG, a critical identifier in this rare, debilitating autoimmune condition. NMOSD primarily causes severe inflammation within the central nervous system, leading to recurrent, serious attacks that can result in permanent disabilities such as vision loss and paralysis. [Published On: 2024-01-16]

Chugai Pharmaceutical's Enspryng Launches in Taiwan for NMOSD Patients

Chugai Pharma Taiwan Ltd., a subsidiary of Chugai Pharmaceutical Co., Ltd., introduced Enspryng in Taiwan. This drug is tailored for adults and adolescents aged 12 and above who test positive for the anti-aquaporin-4 (AQP4) antibody, targeting neuromyelitis optica spectrum disorder (NMOSD). Earlier, the Ministry of Health and Welfare recognized Enspryng as an orphan drug, followed by its approval from the Taiwan Food and Drug Administration. This introduction marks Enspryng as a dedicated treatment for this patient group in Taiwan, showcasing a significant advancement in NMOSD care within the region. [Published On: 2023-10-02]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Devic's Syndrome Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Devic's Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare, Inc., Alexion Pharmaceuticals, Inc by AstraZeneca PLC, Anant Pharmaceuticals Pvt. Ltd., Apple Pharmaceuticals, Cadila Pharmaceuticals Limited, Chugai Pharma Taiwan Ltd., Conscientia Industrial Co., Ltd, Evidentic GmbH, F. Hoffmann-La Roche Ltd, Healthy Life Pharma Pvt. Ltd., Horizon Therapeutics plc by Amgen, Inc., LEXICARE PHARMA PVT. LTD., Merck KGaA, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics, Inc., Samsung Bioepis Co., Ltd. by Samsung Biologics, Teva Pharmaceutical Industries Ltd., TG Therapeutics, Inc., Thermo Fisher Scientific Inc., and West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC.

Market Segmentation & Coverage

This research report categorizes the Devic's Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Corticosteroids
    • Immunosuppressants
    • Plasma Exchange (Plasmapheresis)
  • Distribution Channel
    • Clinics
    • Hospitals
    • Online Pharmacies
  • End User
    • Adult Patients
    • Pediatric Patients
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidences of Devic's Syndrome across the world
      • 5.1.1.2. Efforts to raise awareness for neurological conditions and the emergence of advocacy groups
      • 5.1.1.3. Favorable regulatory approvals and government initiatives to ensure access to Devic's syndrome treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity of the disease and the inability of treatments to tackle Devic's Syndrome
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing initiatives to improve the efficacy and safety of Devic's Syndrome treatment solutions
      • 5.1.3.2. Patient preference for personalized and specific treatment strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Possibility of side effects of the treatment solutions for Devic's Syndrome
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Utilization of corticosteroids for Devic's Syndrome due to their effectiveness in rapidly controlling inflammation
    • 5.2.2. End User: Development of a comprehensive Devic's Syndrome treatment plans for adult patients
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Devic's Syndrome Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Corticosteroids
  • 6.3. Immunosuppressants
  • 6.4. Plasma Exchange (Plasmapheresis)

7. Devic's Syndrome Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Hospitals
  • 7.4. Online Pharmacies

8. Devic's Syndrome Treatment Market, by End User

  • 8.1. Introduction
  • 8.2. Adult Patients
  • 8.3. Pediatric Patients

9. Americas Devic's Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Devic's Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Devic's Syndrome Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Approves Ultomiris for Neuromyelitis Optica Spectrum Disorder, Expanding Its Therapeutic Scope
    • 12.3.2. Health Canada Approves UPLIZNA for Adults with NMOSD
    • 12.3.3. Chugai Pharmaceutical's Enspryng Launches in Taiwan for NMOSD Patients
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. DEVIC'S SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DEVIC'S SYNDROME TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DEVIC'S SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE (PLASMAPHERESIS), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE (PLASMAPHERESIS), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 283. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023